Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS ANNOUNCES NON-BROKERED LIFE OFFERING

Onco-Innovations Ltd. intends to complete a non-brokered private placement of units of the company, pursuant to which it will offer 6,764,069 units at a price of 73.92 cents per unit for aggregate gross proceeds of approximately $5-million pursuant to the listed issuer financing exemption (as defined below). Each unit is composed of one common share and one common share purchase warrant, with each warrant entitling the holder to purchase one share at a price of 90 cents for a period of three years following the closing date of the private placement, which is expected to occur on or about July 10, 2026, subject to certain conditions, including the receipt of all necessary regulatory approvals, including the approval of Cboe Canada Inc.

The private placement will not close unless subscriptions for at least 6,764,069 units have been received. If the minimum subscription is not achieved, all subscription funds will be returned to subscribers in accordance with applicable securities laws.

The net proceeds from the private placement will be used to advance the development of its ONC010 program through key stages of its clinical development pathway, including manufacturing and preclinical testing activities, for the development of the SynoGraph platform, and for general working capital and corporate purposes.

The warrants shall provide that, if the 10-day volume-weighted average trading price of the shares on the Cboe (or such other exchange on which the shares are then listed) is equal to or greater than $1.30 at the close of any trading day, the company may, at its option, accelerate the expiry date of the warrants by issuing a news release announcing that the expiry date of the warrants will be deemed to be the 30th day following the date of such news release.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 (Prospectus Exemptions), the units will be offered for sale to purchasers resident in all provinces of Canada except Quebec pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 as amended by Coordinated Blanket Order 45-935 (Exemptions from Certain Conditions of the Listed Issuer Financing Exemption) as well as certain offshore purchasers. Because the private placement is being completed pursuant to the listed issuer financing exemption, the units issued pursuant to the private placement will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document related to the private placement that can be accessed under the company's issuer profile on SEDAR+ and on the company's website. Prospective investors should read the offering document before making an investment decision.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.